Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ascending Single Dose Study of The Safety, Tolerability, Pharmacokinetics, of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Japanese Male Subjects

Trial Profile

Ascending Single Dose Study of The Safety, Tolerability, Pharmacokinetics, of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Japanese Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2018

At a glance

  • Drugs Danegaptide (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 28 Jan 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Dec 2007 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top